OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
P/E ratio for OmniAb, Inc. (OABI)
P/E ratio as of 2023: -12.15
According to OmniAb, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.15. At the end of 2022 the company had a P/E ratio of -13.75.
P/E ratio history for OmniAb, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -12.15 |
| 2022 | -13.75 |
| 2021 | -30.55 |
| 2020 | -63.83 |
| 2019 | -82.47 |